Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma
Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), which targets the CD20 protein, present in over 80% of...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
2014-09-01
|
| Serier: | Brazilian Journal of Pharmaceutical Sciences |
| Fag: | |
| Online adgang: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502014000300445&lng=en&tlng=en |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|